Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021

June 2021 | 37 pages | ID: NDF444FB0A90EN
Global Markets Direct

Abstracts

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021

SUMMARY

According to the recently published report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
• The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
CombiGene AB
Gila Therapeutics Inc
Takeda Pharmaceutical Co Ltd
XL-protein GmbH
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
CG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYY-1119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
Featured News & Press Releases
Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc
Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
Dec 14, 2020: With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
Oct 30, 2020: CombiGene comments the final preclinical steps
Oct 01, 2020: CombiGene one step closer to clinical trials
Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies
Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
Sep 11, 2020: CombiGene’s new agreement important for future clinical studies
Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by CombiGene AB, 2021
Pipeline by Gila Therapeutics Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by XL-protein GmbH, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021